Background
==========

Although up to 70% of patients with epilepsy have an underlying genetic cause \[[@B1]\], most patients with epilepsy will not receive a molecular diagnosis. Genetic testing for epilepsies is challenging since genetic heterogeneity for this group of conditions is significant. For instance, epilepsy can be caused by mutations in over 260 genes and an accurate diagnosis can be particularly difficult with nonspecific epilepsy phenotypes \[[@B2]\]. Even when epilepsy is associated with additional features, such as microcephaly, the number of genes potentially responsible can still be significant and assessing each gene in turn by Sanger sequencing would be time-consuming and expensive. However, establishing a molecular diagnosis is important for informed genetic counseling, prenatal testing, insight into natural history and increasingly for therapeutic management as there are now many instances where medications are tailored based on molecular results \[[@B3]-[@B5]\].

Whole exome sequencing (WES) has emerged as a very successful tool for novel disease gene discovery \[[@B6]\] and its utility in the rapid and cost-effective analysis of heterogeneous disorders is being established. Both a WES approach and the application of targeted panels of channelopathy or encephalopathy genes have been successful in identifying the molecular cause for many patients with rare epilepsies \[[@B2],[@B7]\]. In addition, WES may offer a rapid and less expensive first line test to establish a molecular diagnosis for disabled patients residing in remote areas where ready access to standard diagnostic assessments can be more challenging. We report here the utility of WES as the initial diagnostic tool for a consanguineous family with four affected adult children with epilepsy, microcephaly and severe intellectual disability from a remote area of Canada.

Case presentation
=================

Clinical findings
-----------------

Four affected siblings (two females and two males) from a consanguineous French Canadian family presented in their 40s and 50s to a satellite genetics clinic for assessment to facilitate genetic counseling for extended family members (Figure [1](#F1){ref-type="fig"}A). Two developmentally normal brothers died in an accidental fire and one living brother is unaffected. The parents were from an isolated community and were distantly related. The four siblings had moderate to severe intellectual disability, epilepsy and microcephaly (Table [1](#T1){ref-type="table"}). A more severe phenotype was seen in the two male siblings, including medically refractory seizures, aggression and self-injury. Due to the difficulty of performing MRI in a remote region and the long differential diagnosis, DNA was sent for WES as an initial investigation.

![**WES identifies a novel frameshift mutation in*WDR62*. (A)** Family pedigree showing the four affected siblings (solid symbols) and unaffected family members (open symbols). Squares represent males, circles females, asterisk denote available DNA. Patient II-1 was selected for WES (black arrow). **(B)** WES in Patient II-1 revealed a homozygous single-base pair insertion (c.1821dupT) in *WDR62* producing a frameshift mutation (p.Arg608Serfs\*26). **(C)** The mutation was validated by Sanger sequencing in all affected siblings (only II-1 and II-2 are shown); parental DNA was unavailable for this study. The mutation is absent in an unaffected control (WT). **(D)** Reported *WDR62* mutations in MCPH2 families. *WDR62* is located on chromosome 19q13.12 and contains 32 exons (NM_001083961.1) encoding 1523 amino acids. For clarity, reported *WDR62* mutations are annotated as peptide changes (grey). Number sign indicates the compound heterozygous mutation present in one reported family \[[@B15]\]. The homozygous single-base pair insertion identified in the French-Canadian family is also shown (red).](1471-2377-14-22-1){#F1}

###### 

Clinical and neuroimaging features of the four MCPH2 patients

               **Patient**                  **II-1**                **II-2**                     **II-3**               **II-4**
  ------------------------------------- ----------------- ---------------------------- ---------------------------- -----------------
                 Gender                         F                      M                            M                       F
         Age at assessment (yrs)               59                      56                           55                     53
          **Clinical features**                                                                                     
               Height (cm)                     158                    154                          166                     154
            Height percentile                10-25th                 \<5th                         5th                   5-10th
   Occipito-frontal circumference (cm)        48.5                     52                           51                     48
   Occipito-frontal circumference (SD)     -4 to -5 SD            -2 to -3 SD                     -3 SD                -4 to -5 SD
            Sloping forehead                   \+                      \+                           \+                     \+
         Intellectual disability         Moderate-severe             Severe                       Severe             Moderate-severe
                Behaviour                   Pleasant        Self injurious behaviour     Self injurious behaviour       Pleasant
                  Tone                       Normal                Hypertonia                   Hypertonia               Normal
              Sensory exam                   Normal                  Normal                       Normal                 Normal
                Reflexes                     Normal        Hyperreflexia/ankle clonus   Hyperreflexia/ankle clonus       Normal
       Bladder/bowel incontinence              +/-                    +/+                          +/+                     +/-
        **Neuroimaging features**                                                                                   
              Microcephaly                     \+                      Nd                           Nd                     \+
             Polymicrogyria                    \-                      Nd                           Nd                     \-
          Cerebellar hypoplasia                \-                      Nd                           Nd                     \-
           Cortical thickenng                  \-                      Nd                           Nd                     \-
       Corpus callosum hypoplasia              \-                      Nd                           Nd                     \-

*Abbreviations*: *F* female, *M* male, *nd* not determined.

Genetic studies
---------------

Genomic DNA was extracted from whole blood obtained from the four affected individuals using the QIAamp DNA Blood Kit (Qiagen, CA, USA). DNA from Patient II-1 underwent WES. Using target capture with the Agilent SureSelect 50 Mb All Exon kit (Agilent Technologies, Santa Clara, CA) and sequencing of 100 bp paired end reads on Illumina Hiseq, we generated over 15 Gb of sequence for the sample such that approximately 90% of the coding bases of the exome defined by the consensus coding sequence (CCDS) project were covered by at least 20 reads. WES data was analyzed as previously described \[[@B8]\] and non-synonymous variants (frameshift and non-frameshift indels, single nucleotide variants (SNV) including stop-gain and missense SNVs, and splicing and splicing-extending variants) were identified as rare when they had a frequency of less than 1% in the 1000 genomes pilot release (Nov 2010) and in 100 in-house controls. We then compared two approaches to examine this subset of WES variants (Figure [2](#F2){ref-type="fig"}).

![**Exome sequencing workflow.** Exome sequencing was performed on isolated DNA from Patient II-1. The data was filtered to identify non-synonymous sequence variants including frameshift and non-frameshift indels, single nucleotide variants (SNV) including stop-gain and missense SNVs, and splicing and splicing-extending variants. Variants with a frequency of less than 1% in the 1000 genomes pilot release (Nov 2010) and in 100 in-house controls were then identified. The first method of analysis focused on rare homozygous variants (Method 1) and a second, simpler approach, focused only on rare variants in disease genes known to cause microcephaly/epilepsy (Method 2). Both methods identified the homozygous mutation in *WDR62* as the cause of the neurodevelopmental disorder in this family.](1471-2377-14-22-2){#F2}

Following our preliminary filtering steps that identified 183 rare non-synonymous variants, we examined the sequencing data for homozygous variants as the pedigree was consistent with autosomal recessive inheritance and the parents were distantly related (see Method 1, Figure [2](#F2){ref-type="fig"}). WES identified ten exome-wide homozygous variants including a rare variant in *WDR62*, encoding a protein essential to cerebral cortex development and known to cause microcephaly \[[@B9]-[@B11]\] (Figure [1](#F1){ref-type="fig"}B) and thus felt to be a strong candidate gene for the disorder in this family. The *WDR62* mutation identified is a novel homozygous single-base pair insertion NM_001083961.1:c.1821dupT) producing a frameshift mutation (p.Arg608Serfs\*26) in exon 14 (Figure [1](#F1){ref-type="fig"}C). The protein-truncating mutation is absent from the 6500 exomes in the NHLBI Exome Variant Server. We next examined the WES data using a second approach to identify all rare variants in genes known to be associated with epilepsy and microcephaly (see Method 2, Figure [2](#F2){ref-type="fig"}); the same mutation in *WDR62* was identified as the only candidate.

The mutation in *WDR62* was validated by Sanger sequencing in the other three siblings. After the diagnosis, unenhanced MRI of the brain was performed in both sisters and demonstrated microcephaly without polymicrogyria, cerebellar hypoplasia, cortical thickening or corpus callosum hypoplasia. Patient II-2 died suddenly of a cardiac arrest but was not known to have cardiac disease prior to the fatal event; the family declined an autopsy.

Discussion
==========

Primary autosomal recessive microcephaly (MCPH, OMIM 251200) is a genetically heterogeneous group of disorders characterized by congenital microcephaly, cognitive impairment and variable epilepsy \[[@B12]\]. Mutations in *WDR62* are associated with primary microcephaly-2 (MCPH2, OMIM 604317), which is believed to account for 10% of all cases of MCPH \[[@B13]\]. Clinical features of MCPH2 include epilepsy, marked cognitive impairment, incontinence, sloping forehead and prominent ears. Radiological features are variable and may include polymicrogyria, corpus callosum hypoplasia, heterotopias, pachygyria with cortical thickening, lissencephaly and schizencephaly, although patients can present with isolated microcephaly \[[@B14]-[@B18]\]. To date, 34 families have been identified with mutations in *WDR62*, the reported affected individuals ranging in age from infancy to mid-teens \[[@B14]-[@B18]\].We present here the oldest patients known to have *WDR62* mutations associated with MCPH, providing additional insight into the natural history and phenotypic spectrum of this disorder. It is unclear whether the sudden cardiac death for Patient II-2 is associated with *WDR62* mutations or an unrelated cardiac event. Of the mutations in *WDR62* reported thus far, approximately half have been frameshift mutations, as described here, distributed throughout the gene and predicted to result in premature truncation of the protein (Figure [1](#F1){ref-type="fig"}C).

At least ten genes have been associated with MCPH \[*ASPM, MCPH1, WDR62, CDK5RAP2, CASC5, CENPJ, STIL, CEP135, CEP152* and *ZNF335*\] and are implicated in proliferation and migration of neuronal progenitors during embryonic cortical development \[[@B19]\]. Clinical-radiological features have not been loci-specific and MCPH patients remain phenotypically indistinguishable \[[@B13]\]. Thus, conventional molecular testing can be a long and expensive process and may not yield a diagnosis. Currently, sequential analysis of the eight clinically available MCPH genes would total more than \$22,000 USD. Alternatively, eight of the ten MCPH genes could be sequenced as part of a microcephaly panel for \$7,000 USD (<http://www.centogene.com> accessed November 6^th^, 2013, eight genes). Comparatively, WES would interrogate all ten microcephaly genes and is currently available in clinical laboratories at \$5000 USD per patient, making it a cost-effective solution for rapid diagnosis in the clinic.

Conclusion
==========

We studied four siblings from a consanguineous French Canadian family presenting with microcephaly, severe developmental delay and epilepsy. Given their relatively nonspecific phenotype which did not suggest a single likely candidate gene, sequential gene testing was not undertaken. Alternatively, WES provided a cost-effective and rapid method to identify the genetic cause of epilepsy and microcephaly in this family. We highlight, that particularly for patients in remote areas, WES via DNA blood/saliva offers a non-invasive and readily accessible method for shortening the diagnostic process for these patients.
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